Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Successfully Develops \u201cChange History\u201d for its Clinical Trial Product for Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company\u2019s Pancreatic Cancer Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"H.C. Wainwright","pharmaFlowCategory":"D","amount":"$70.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"Heidelberg Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"PharmaCyte Biotech","sponsor":"CBSET","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Ifosfamide

    Menu

    Ifosfamide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PharmaCyte Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

              Details:

              The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology.

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: CBSET

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 21, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

              Details:

              The study has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypCaps plus ifosfamide pancreatic cancer therapy for the treatment of malignant ascites.

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Heidelberg Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 19, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

              Details:

              Analysis after 18 months in storage at -80oC, the unfrozen CypCaps product passed all the specified tests, including cell viability, enzyme activity, cell potency, pH, label check, capsule appearance and integrity.

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

              Details:

              PharmaCyte is positioned to immediately move into a fully funded clinical trial in LAPC should the FDA lift the clinical hold.

              Lead Product(s): Encapsulated Live Cells,Ifosfamide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $90.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 25, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

              Details:

              The Company intends to use the net proceeds of this offering to complete activities requested by the U.S. Food and Drug Administration (FDA) to address the FDA’s clinical hold on its Investigational New Drug application (IND).

              Lead Product(s): Encapsulated Live Cells,Ifosfamide

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: H.C. Wainwright

              Deal Size: $70.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

              Details:

              PharmaCyte's CypCapsTM, is a genetically engineered human cells encapsulated using the Cell-in-a-Box® technology. PharmaCyte is conducting a Phase 2b study to evaluate the efficacy and safety of CypCaps in combination with low-dose ifosfamide vs chemoradiation therapy.

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: H.C. Wainwright

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering August 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy

              Details:

              The DMF provides all confidential and detailed information covering the production of the CypCaps™ final product, which was produced by Austrianova and will be used in PharmaCyte’s planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 27, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PharmaCyte Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PharmaCyte Biotech Successfully Develops “Change History” for its Clinical Trial Product for Pancreatic Cancer

              Details:

              PharmaCyte has successfully completed development of the “change history” information and data for CypCaps™ (2nd generation product) compared to CapCell™ (1st generation product).

              Lead Product(s): CypCaps,Ifosfamide

              Therapeutic Area: Oncology Product Name: CypCaps

              Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY